Intervention Review

You have free access to this content

Agomelatine versus other antidepressive agents for major depression

  1. Giuseppe Guaiana1,*,
  2. Sumeet Gupta2,
  3. Debbie Chiodo3,
  4. Simon JC Davies4,
  5. Katja Haederle5,
  6. Markus Koesters5

Editorial Group: Cochrane Common Mental Disorders Group

Published Online: 17 DEC 2013

Assessed as up-to-date: 1 JUL 2013

DOI: 10.1002/14651858.CD008851.pub2


How to Cite

Guaiana G, Gupta S, Chiodo D, Davies SJC, Haederle K, Koesters M. Agomelatine versus other antidepressive agents for major depression. Cochrane Database of Systematic Reviews 2013, Issue 12. Art. No.: CD008851. DOI: 10.1002/14651858.CD008851.pub2.

Author Information

  1. 1

    Western University, Department of Psychiatry, St Thomas, Ontario, Canada

  2. 2

    Tees, Esk & Wear Valleys NHS Foundation Trust, General Adult Psychiatry, Darlington, Durham, UK

  3. 3

    Centre for Addiction and Mental Health, Social and Epidemiological Research Department, London, Ontario, Canada

  4. 4

    University of Bristol, School of Social and Community Medicine, Bristol, UK

  5. 5

    Ulm University, Department of Psychiatry II, Guenzburg, Germany

*Giuseppe Guaiana, Department of Psychiatry, Western University, Saint Thomas Elgin General Hospital, 189 Elm Street, St Thomas, Ontario, N5R 5C4, Canada. Giuseppe.Guaiana@sjhc.london.on.ca. gguaiana@stegh.on.ca.

Publication History

  1. Publication Status: New
  2. Published Online: 17 DEC 2013

SEARCH

References

References to studies included in this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
CAGO2303 {unpublished data only}
  • Novartis Pharmaceuticals. A placebo- and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine (25 or 50 mg) in the treatment of major depressive disorder (MDD) [NCT00463242]. ClinicalTrials.gov [www.clinicaltrials.gov] [accessed 10 November 2012] 2009.
  • Novartis Pharmaceuticals. An 8-week, multicenter, randomized, double-blind, placebo-and paroxetine-controlled study of the efficacy, safety and tolerability of agomelatine 25 or 50 mg given once daily in the treatment of Major Depressive Disorder (MDD). http://www.novctrd.com/ctrdWebApp/clinicaltrialrepository/displayFile.do?trialResult=2659 [accessed 10 November 2012] 2009.
CL3-022 {unpublished data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
  • European Medicines Agency. CHMP Assessment report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf. [Accessed 22 January 2013] 2006.
CL3-023 {unpublished data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
  • European Medicines Agency. CHMP Assessment report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf. [Accessed 22 January 2013] 2006.
CL3-024 {unpublished data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
  • European Medicines Agency. CHMP Assessment report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf. [Accessed 22 January 2013] 2006.
Corruble 2013 {published data only}
  • Corruble E, Belaidi C, Goodwin GM. Agomelatine versus escitalopram in major depressive disorders. European Psychiatry [abstracts from the 19th European Congress of Psychiatry, EPA 2011 Mar 12-15; Vienna, Austria] 2011;26(S1):619.
  • Corruble E, de Bodinat C, Belaidi C, Goodwin GM. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial. International Journal of Neuropsychopharmacology 2013:1-16 [epub ahead of print].
Hale 2010 {published data only (unpublished sought but not used)}
  • Hale A. Efficacy and safety of agomelatine (25 mg/day with potential adjustment to 50 mg) given orally for eight weeks in out-patients with severe major depressive disorder: a randomised double-blind, parallel groups, international study versus selective serotonin reuptake inhibitor (SSRI) with a double-blind extension period of 16 weeks. Controlled-Trials.com 2008 (http://www.controlled-trials.com/ISRCTN19313268/servier).
  • Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. International Clinical Psychopharmacology 2010;25(6):305-14.
Kasper 2010 {published data only (unpublished sought but not used)}
  • Kasper S, Hajak G, Wulff K, Hoogendijk WJG, Montejo AL, Smeraldi E, et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline [ISRCTN49376288]. Journal of Clinical Psychiatry 2010;71(2):109-20.
Kennedy 2008 {published data only (unpublished sought but not used)}
  • Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. Journal of Clinical Psychopharmacology 2008;28(3):329-33.
Lemoine 2007 {published data only (unpublished sought but not used)}
  • Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry 2007;68(11):1723-32.
Loo 2002a {published data only}
  • Loo H, Hale A, D'haenen H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International Clinical Psychopharmacology 2002;17(5):239-47.
Martinotti 2012 {published data only}
  • Martinotti G, Sepede G, Di Nicola M, Di Iorio G, Gambi F, De Risio L, et al. Agomelatine versus venlafaxine in the treatment of anhedonia in major depressive subjects: A pilot study [oral presentation]. European Psychiatry [abstracts of the 20th European Congress of Psychiatry, EPA. 2012 Mar 3-6; Prague Czech Republic] 2012;27(Suppl 1):O-35.
  • Martinotti G, Sepede G, Gambi F, Di Iorio G, De Berardis D, Di Nicola M, et al. Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. Journal of Clinical Psychopharmacology 2012;32(4):487-91.
Quera-Salva 2011 {published data only (unpublished sought but not used)}
  • Quera-Salva M-A, Hajak G, Philip P, Montplaisir J, Keufer-Le Gall S, Laredo J, et al. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology 2011;26(5):252-62.
  • Quera-Salva M-A, Servier Laboratories. Effects of agomelatine on sleep electroencephalogram parameters compared to selective serotonin reuptake inhibitors in patients with major depressive disorder: a six-week randomised, double-blind parallel group study versus comparator, followed by a double-blind optional treatment extension period up to six months [ISRCTN44737909; CL3-20098-056; EUCTR2006-004716-48]. Controlled-Trials.com [www.controlled-trials.com] 2007.
Shu 2013 {published data only}
  • Shu L, Sulaiman AH, Huang YS, et al. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder. Asian Journal of Psychiatry 2013;(in press). [DOI: 10.1016/j.ajp.2013.09.009]
  • Shu L, Zhang Y, Servier Laboratories. Efficacy and safety of agomelatine with flexible dose (25 mg/day with potential adjustment at 50 mg) given orally for 8 weeks in out-patients with Major Depressive Disorder. A randomised flexible dose double-blind international multicentric study with parallel groups, versus fluoxetine (20 mg/day with potential adjustment at 40 mg) [ChiCTR-TRC-11001668]. Chinese Clinical Trial Registry [http://www.chictr.org/en] 2011.

References to studies excluded from this review

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
CAGO2301 {published data only}
  • Novartis Pharmaceuticals. An 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1 mg sublingual tablets administered once daily in patients with major depressive disorder (MDD) [NCT01110889; CAGO178C2301]. ClinicalTrials.gov [www.clinicaltrials.gov] 2010.
CAGO2302 {published data only}
  • Novartis Pharmaceuticals. A 8-week, randomized, double-blind, placebo-controlled, parallel-group, multi-center study of the efficacy and safety of agomelatine 0.5 mg and 1 mg sublingual tablets administered once daily in patients with major depressive disorder (MDD) [NCT01110902; CAGO178C2302]. ClinicalTrials.gov [www.clinicaltrials.gov] 2010.
CAGO2304 {published data only}
  • Novartis Pharmaceuticals. A 52-week, randomized, double-blind, placebo-controlled, multi-center, parallel-group study of the long-term efficacy, tolerability and safety of agomelatine 25 and 50 mg in the prevention of relapse of major depressive disorder (MDD) following open-label treatment of 16-24 weeks [NCT00467402; CAGO178A2304]. ClinicalTrials.gov [www.clinicaltrials.gov] 2007.
CL2-009 {published data only}
  • Servier Laboratories. Efficacy and safety of 3 doses (0.25, 0.5 and 1mg/day) of agomelatine sublingual administration over an 8-week treatment period, in out-patients with Major Depressive Disorder. An 8-week randomised, double-blind, fixed dose, international multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period of 16 weeks [CL2-90098-009; EUCTR2009-014045-92]. EU Clinical Trials Register [.www.clinicaltrialsregister.eu] 2009.
CL3-021 {published data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
CL3-025 {published data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
CL3-026 {published data only}
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000915/WC500046226.pdf. [Accessed 22 October 2012] 2008.
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. [Accessed 25 October 2012] 2009.
Corral 2009 {published data only}
  • Corral RM, Servier Laboratories. Efficacy and safety of three dose regimens of agomelatine (10, 25, 25 - 50 mg) versus placebo given once a day for 6 weeks in out-patients suffering from moderate to severe major depressive disorder: a 6-week randomised, double-blind, placebo-controlled, parallel groups study followed by a double-blind optional 18-week extension period [ISRCTN10845256; CL3-20098-069; EUCTR2009-011238-84]. Controlled-Trials.com [www.controlled-trials.com] 2009.
Goodwin 2009 {published data only}
  • Goodwin GM, Emsley R, Rembry S, Rouillon F, Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial [ISRCTN53193024]. Journal of Clinical Psychiatry 2009;70(8):1128-37.
Heun 2013 {published data only}
  • Heun R, Ahokas A, Boyer P, Gimenez-Montesinos N, Pontes-Soares F, Olivier V. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. Journal of Clinical Psychiatry 2013;74(6):587-94.
  • Heun R, Servier Laboratories. Efficacy and safety of agomelatine oral administration (25 to 50 mg/day) in elderly patients suffering from major depressive disorder: an 8-week, randomised, double-blind, flexible-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 16 weeks [ISRCTN57507360; CL3-20098-070; EUCTR2009-011795-29]. Controlled-Trials.com [www.controlled-trials.com] 2010.
Kennedy 2006 {published data only}
Loo 2002b {published data only}
  • Loo H, Dalery J, Macher JP, Payen A. Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5ht2c receptors antagonist, in the treatment of major depressive disorders. L'Encephale 2002;28(4):356-62.
Olie 2007 {published data only}
  • Olie JP, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. International Journal of Neuropsychopharmacology 2007;10(5):661-73.
Rouillon 2008 {published data only}
  • Rouillon F, Servier Laboratories. Efficacy and safety of two doses of S 90098 (1 and 2 mg/day), sublingual formulation for 8 weeks in out-patients with major depressive disorder: An 8-week randomised, double-blind, fixed dose, international, multicentre, placebo-controlled study with parallel groups, followed by an extension double-blind treatment period for 16 weeks [ISRCTN38378163; CL2-90098-005]. Controlled-Trials.com [www.controlled-trials.com] 2008.
Saletu 2011 {published data only}
  • Saletu M, Saletu-Zyhlarz GM, Anderer P, Rosales-Rodriguez S, Saletu B. On the acute effect of agomelatine on sleep and awakening in major depression: controlled polysomnographic and psychometric studies [abstract]. Somnologie [abstracts of the 19th Jahrestagung der DGSM; 2011 Nov 10-12; Mannheim Germany] 2011.
Save 2011 {published data only}
  • Save D, Precise Chemipharma Pvt Ltd. A multicentric, open-label, randomized, comparative, parallel-group, active-controlled Phase III clinical trial of the efficacy and safety of agomelatine oral tablets in patients with major depressive disorder [CTRI/2011/08/001946]. Clinical Trials Registry - India [http://ctri.nic.in] 2011.
Serfaty 2010 {published data only}
  • Serfaty MA, Osborne D, Buszewicz MJ, Blizard R, Raven PW. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. International Clinical Psychopharmacology 2010;25(3):132-42.
Stahl 2010 {published data only}
  • Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial [NCT00411242]. Journal of Clinical Psychiatry 2010;71(5):616-26.
Tseng 2007 {published data only}
  • Tseng M-C. The effect of agomelatine or fluoxentine on heart rate variability in patients with major depressive disorder [NCT00451490]. ClinicalTrials.gov [www.clinicaltrials.gov] 2007.
Zajecka 2010 {published data only}
  • Zajecka J, Schatzberg A, Stahl S, Shah A, Caputo A, Post A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology 2010;30(2):135-44.

References to studies awaiting assessment

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
CL3-027 {published data only}
  • European Medicines Agency. CHMP Assessment report for Valdoxan [Procedure No. EMEA/H/C/656, Doc. Ref. EMEA/CHMP/87018/2006].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000656/WC500070527.pdf. [Accessed 22 January 2013] 2006.
CL3-048 {published data only}
  • Bougerol T, Servier Laboratories. Efficacy of agomelatine given orally on the quality of remission in elderly depressed patients, after a 12-week treatment period. A randomised, double-blind, flexible-dose international multicentre study with parallel groups versus SSRI drug. Twelve-week treatment plus optional continuation for 12 weeks [ISRCTN68222771; CL3-20098-048; EUCTR2005-002388-95]. Controlled-Trials.com [www.controlled-trials.com] 2006.
CL3-062 {published data only}
  • Marey C, Servier Laboratories. Evaluation of efficacy and clinical benefit of agomelatine in patients with major depressive disorder compared to serotonin-norepinephrine reuptake inhibitor (SNRI) [ISRCTN96725312; CL3-20098-062; EUCTR2008-004642-92]. Controlled-Trials.com [www.controlled-trials.com] 2009.
CL3-073 {published data only}
  • Lejoyeux M, Servier Laboratories. Initiation of agomelatine after antidepressant treatment in outpatients suffering major depressive disorder [ISRCTN97599615; CL3-20098-073; EUCTR2010-019556-44]. Controlled-Trials.com [www.controlled-trials.com] 2010.
CRSC11003 {published data only}
  • Cadila Pharmaceuticals Limited. A randomized, multi-center, double blind, controlled, comparative study of the efficacy and safety of agomelatine 25 mg (or 50 mg) and paroxetine 20mg (or 30 mg) in patients with major depressive disorder (MDD) [CTRI/2012/03/002480; CRSC11003]. Clinical Trials Registry - India [http://ctri.nic.in] 2012.
CTRI/2011/04/001659 {published data only}
  • Borgharkar S, Sun Pharmaceutical Industries Ltd. Evaluation of efficacy and safety of agomelatine versus venlafaxine ER in the treatment of major depressive disorder. Clinical Trials Registry - India [http://ctri.nic.in] 2011.
Karaiskos 2013 {published data only}
Montgomery 2004 {published data only}
  • Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation. International Clinical Psychopharmacology 2004;19(5):271-80.
Vasile 2011 {published data only}
  • Vasile D, Vasiliu O, Vasile ML, Terpan M, Ojog DG. Agomelatine versus selective serotoninergic reuptake inhibitors in major depressive disorder and comorbid diabetes mellitus [conference abstract]. European Neuropsychopharmacology [abstracts from the 24th Congress of the European College of Neuropsychopharmacology, ECNP 2011 Paris France, 3-7 Sept] 2011;21(Suppl 3):S383-4.

References to ongoing studies

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
CL3-060 {published data only}
  • Servier Laboratories. Effects of agomelatine versus escitalopram on emotional experiences in outpatients suffering from major depressive disorder. An exploratory, randomised, double-blind, international, multicentre study with parallel groups: agomelatine (25 to 50 mg/day) versus escitalopram (10 to 20 mg/day) over a 6-month period [EUCTR2011-005320-17-GB; CL3-20098-060]. EU Clinical Trials Register [www.clinicaltrialsregister.eu] [Accessed 20 September 2013] 2012.
CL3-074 {published data only}
  • Shah A, Rajarshi M. Efficacy and safety of agomelatine with flexible dose (25 mg/day with blinded adjustment at 50 mg) given orally for 8 weeks in Indian outpatients with major depressive disorder. A randomised double-blind national multicentric study with parallel groups, versus sertraline (50 mg/day with blinded potential adjustment at 100 mg) [CTRI/2010/091/006081; CL3-20098-074]. Clinical Trials Registry - India [http://ctri.nic.in] [Accessed 20 September 2013] 2012.
CL3-083 {published data only}
  • Udristoiu T, Servier Laboratories. Early effect of agomelatine on general interest in outpatients suffering major depressive disorder: a parallel group, randomised, double-blind, multicentre study [ISRCTN28327843; CL3-20098-083]. Controlled-Trials.com [www.controlled-trials.com] [Accessed 20 September 2013] 2011.
GENRAS {published data only}
  • Medizinische Universität Wien Univ Klinik f Psychiatrie und Psychotherapie. GENRAS (GENetics of Response to Agomelatine vs. EScitalopram) [EUCTR2010-019423-61-AT]. EU Clinical Trials Register [www.clinicaltrialsregister.eu] [Accessed 20 September 2013] 2010.
Lundbeck 2011 {published data only}
  • H Lundbeck A/S. A randomised, double-blind, parallel-group, active-controlled, flexible dose study evaluating the effects of Lu AA21004 versus agomelatine in adult patients suffering from major depressive disorder with inadequate response to antidepressant treatment [NCT01488071; EUCTR2011-002362-21]. ClinicalTrials.gov [www.clinicaltrials.gov] [Accessed 20 September 2013] 2011.
NCT01483053 {published data only}
  • Baker IDI Heart and Diabetes Institute. A randomised trial investigating the cardiovascular effects of agomelatine and escitalopram in patients with major depressive disorder [NCT01483053]. ClinicalTrials.gov [www.clinicaltrials.gov] [Accessed 20 September 2013] 2011.

Additional references

  1. References to studies included in this review
  2. References to studies excluded from this review
  3. References to studies awaiting assessment
  4. References to ongoing studies
  5. Additional references
AHRQ 2007
  • Agency for Healthcare Research and Quality. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. http://www.effectivehealthcare.ahrq.gov/ehc/products/7/61/Antidepressants_Executive_Summary.pdf (accessed 9 April 2010).
Als-Nielsen 2003
Altman 1996
APA 1980
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorder (DSM-III), 3rd edition. American Psychiatric Press, 1980.
APA 1987
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R), 3rd edition revised. American Psychiatric Publishing, 1987.
APA 1994
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th edition. American Psychiatric Publishing, 2004.
APA 2000
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) 4th Edition - revised. American Psychiatric Publishing, 2000.
APA 2000a
  • American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Journal of Psychiatry 2000;157:1-45.
Barbui 2004
Beck 1987
  • Beck AT, Steer R. Beck Depression Inventory. Psychological Corporation, 1987.
Bhandari 2004
  • Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, et al. Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials. CMAJ 2004;170:477-80.
Boissel 1999
  • Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. Comparison of the indices and their use. Therapie 1999;54:405-11.
Bollini 1999
  • Bollini P, Pampallona S, Tibaldi G, Kupelnick B, Munizza C. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. British Journal of Psychiatry 1999;174:297-303.
Buchkowsky 2004
Cipriani 2009
  • Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JPT, Churchill R, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009;373:746-58.
Clayton 2006
  • Clayton AH, Montejo AL. Major depressive disorder, antidepressants,and sexual dysfunction. Journal of Clinical Psychiatry 2006;67(Suppl 6):33-7.
Cohen 1960
Deeks 2000
  • Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; Cape Town, South Africa. 2000 Oct 25-28th.
Dolder 2008
  • Dolder CR, Nelson M, Snider M. Agomelatine treatment  of major depressive disorder. The Annals of Pharmacotherapy 2008;421:822-31.
Dording 2002
  • Dording CM, Mischoulon D, Petersen TJ, Kornbluh R, Gordon J, Nierenberg AA, et al. The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. Annals of Clinical Psychiatry 2002;14:143-7.
Elbourne 2002
  • Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31:140-9.
EMEA 2009
  • European Medicines Agency. CHMP Assessment report for Thymanax [Procedure No. EMEA/H/C/000916, Doc. Ref. EMEA/97539/2009].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000916/WC500038315.pdf. (Accessed 25 October 2012) 2009.
Feighner 1972
Fournier 2010
  • Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010;303:47-53.
Furukawa 2005
  • Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20:49-52.
Furukawa 2006
  • Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59:7-10.
Guy 1976
  • Guy W (editor). ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education and Welfare, 1976.
Guyatt 2008
  • Guyatt GH, Oxman AD, Vist GE, Junz R, Falck-Vitter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924-6.
Hamilton 1960
Hansen 2005
  • Hansen RA, Gartlhner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Annals of Internal Medicine 2005;143:415-26.
Higgins 2011
  • Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester: John Wiley & Sons.
Howland 2011
  • Howland RH. Publication bias and outcome reporting bias: agomelatine as a case example. Journal of Psychosocial Nursing and Mental Health Services 2011;49:11-4.
Kasper 2008
  • Kasper S, Laigle L, Baylè F. Superior antidepressant efficacy of agomelatine vs sertraline: A randomized, double-blind study. Poster presentation 21st ECNP Congress, Barcelona, Spain. 30 August - 3 September 2008.
Kasper 2013
  • Kasper S, Corruble E, Hale A, Lemoine P, Montgomery SA, Quera-Salva MA. Antidepressant efficacy of agomelatine versus SSRI/SNRI: results from a pooled analysis of head-to-head studies without a placebo control. International Clinical Psychopharmacology 2013;28:12-9.
Kessler 2003
  • Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289:3095-105.
Khan 2003
  • Khan A, Khan SR, Walens G, Kolts R, Giller EL. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports. Neuropsychopharmacology 2003;28:552-7.
Koesters 2013
  • Koesters M, Guaiana G, Cipriani A, Becker T, Barbui C. Agomelatine efficacy and acceptability revisited: systematic review and meta-analysis of published and unpublished randomised trials. The British Journal of Psychiatry 2013;203(3):179-87.
Lam 2009
  • Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT). Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III Pharmacotherapy. Journal of Affective Disorder 2009;117 Suppl 1:26-43.
Lexchin 2003
Lundh 2012
Middleton 2001
Millan 2003
  • Millan MG, Gobert A, Lejeune F, Dekeyne A, Newman-Tancredi A, Pasteau V, et al. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. Journal of Pharmacology and Experimental Therapeutics 2003;306:954-64.
Montgomery 1979
Müller 2003
  • Müller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery Asberg depression rating scale (MADRS). Journal of Affective Disorders 2003;77(3):255-60.
NICE 2004
  • National Institute of Clinical Excellence. Depression: management of depression in primary and secondary care. National Institute of Clinical Excellence, 2004.
Novartis 2012
  • Novartis. Annual report 2011. http://www.novartis.com/downloads/investors/reports/novartis-annual-report-2011-en.pdf [Accessed 20 June 2013] 2012.
Oxman 1992
Popoli 2009
Prescrire 2013
  • Agomelatine: a review of adverse effects. Prescrire International 2013;136:70-1.
Radloff 1977
  • Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological Measurement 1977;1:385-401.
Rosenbaum 2010
  • Rosenbaum SE, Glenton C, Oxman AD. Summary-of-findings tables in Cochrane reviews improved understanding and rapid retrieval of key information. Journal of Clinical Epidemiology 2010;63:620-6.
San 2008
Servier 2013
  • Servier Laboratories Ltd. Agomelatine (Valdoxan): monitor liver function and do not use in people with high transaminase levels (>3 x ULN) or ≥ 75 years. http://www.servier.co.uk/pdfs/direct-healthcare-professional-communication.pdf [Accessed 20 September 2013] 2013.
Singh 2011
  • Singh SP, Singh V, Kar N. Efficacy of agomelatine in major depressive disorder: meta-analysis and appraisal. International Journal of Neuropsychopharmacology 2011;23:1-12.
Spitzer 1978
Taylor 2009
  • Taylor D, Paton C, Kapur S. The Maudesley Prescribing Guidelines. The Maudsley Prescribing Guidelines. Informa Healthcare, 2009.
WHO 1978
  • World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). World Health Organization, 1978.
WHO 1992
  • World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). World Health Organization, 1992.
WHO 2008
  • World Health Organization. The Global Burden of Disease. 2004 update. World Health Organization, 2008.